Global Smart Implants Market Outlook, 2031

The global smart implants industry covers implanted medical devices that contain sensors, electronics, wireless communication or closed-loop control, allowing them to monitor physiological signals, report data to clinicians or adjust therapy automatically. Examples include orthopaedic implants with embedded sensors that track joint motion and recovery, leadless and connected pacemakers and defibrillators, implantable cardiac monitors, implantable haemodynamic sensors such as Abbott's CardioMEMS pulmonary artery pressure sensor, implantable continuous glucose monitors such as Senseonics' Eversense, closed-loop spinal cord and deep brain stimulators that sense neural signals and adjust stimulation, cochlear implants with smart processing, smart stents and drug delivery implants, and brain-computer interfaces that record brain activity to control external devices. Major companies include Medtronic, Abbott, Boston Scientific, Zimmer Biomet with Canary Medical, Stryker, Biotronik, Cochlear, Senseonics, Nevro, Saluda Medical, and brain-computer interface developers Neuralink, Synchron, Precision Neuroscience, Paradromics and Blackrock Neurotech. These devices depend on miniaturised electronics, long-life batteries or wireless power, biocompatible materials, secure wireless communication and cloud platforms that turn implant data into clinical insights.

Smart implants have moved from concept to routine clinical use in several areas. Remote monitoring of connected pacemakers, defibrillators and insertable cardiac monitors has become standard in cardiology, and Abbott's AVEIR DR, approved in July 2023, became the first dual-chamber leadless pacemaker system, using wireless communication between two implants. In orthopaedics, Zimmer Biomet's Persona IQ, authorised in 2021 with sensors from Canary Medical, became the first smart knee implant to transmit data on patient recovery. Closed-loop neuromodulation has advanced: Medtronic's Inceptiv spinal cord stimulator, approved in April 2024, senses spinal signals and adjusts therapy automatically, and Medtronic's BrainSense adaptive deep brain stimulation was approved in 2025 for Parkinson's disease. In diabetes, the FDA approved Senseonics' Eversense 365, an implantable glucose sensor lasting a full year, in September 2024. Brain-computer interfaces have drawn intense attention: Neuralink implanted its first human patient in January 2024 and has since expanded trials, Synchron has implanted its stentrode device in patients, Precision Neuroscience received FDA clearance for a temporary cortical electrode array in April 2025, and Paradromics received approval to begin a clinical study and to expand compatibility with personal devices in 2026. Challenges include battery life, cybersecurity, data management, reimbursement and demonstrating that data improves outcomes.

Market Dynamics Market Drivers • Demand for Remote Monitoring and Personalised CareHealth systems want to monitor patients with chronic heart disease, diabetes, neurological conditions and joint replacements outside hospital, detect problems early and reduce readmissions. Smart implants provide continuous objective data that can guide treatment, and reimbursement for remote monitoring in the United States and other countries supports adoption. Ageing populations with multiple chronic diseases increase the number of candidates.
• Advances in Miniaturisation, Sensing and Closed-Loop ControlImprovements in microelectronics, low-power wireless communication, battery technology, energy harvesting and biocompatible materials allow more capability in smaller implants. Closed-loop systems that sense and respond automatically, such as adaptive spinal cord and deep brain stimulation, improve therapy and reduce the need for manual adjustment. AI helps interpret large volumes of implant data.

Market Challenges • Cybersecurity, Data Management and PrivacyConnected implants can be vulnerable to hacking or unauthorised access, and regulators require manufacturers to build in cybersecurity protections and update software securely. The large volumes of data generated must be managed, interpreted and integrated into clinical workflows without overwhelming clinicians. Patient data privacy and ownership raise legal and ethical questions, particularly for brain-computer interfaces.
• Cost, Battery Life and Evidence of BenefitSmart implants cost more than conventional implants, and payers require evidence that the data or closed-loop functions improve outcomes or reduce costs. Battery life limits some devices, requiring replacement surgery, and adding electronics increases complexity and potential failure points. Surgical risks and long-term reliability, especially for brain implants, must be demonstrated in larger studies.

Market Trends • Brain-Computer InterfacesBrain-computer interfaces that record neural signals to allow people with paralysis to control computers, communicate or move robotic limbs are advancing through clinical trials by Neuralink, Synchron, Precision Neuroscience, Paradromics, Blackrock Neurotech and Chinese developers. Regulators have granted breakthrough designations, and investment has grown rapidly. Companies are developing fully implanted wireless systems and integrating them with consumer devices.
• Smart Orthopaedic and Leadless Cardiac ImplantsOrthopaedic companies are adding sensors to knee, hip, spine and trauma implants to measure motion, load and healing, providing data for rehabilitation and early detection of problems. In cardiology, leadless pacemakers, including multi-chamber systems that communicate wirelessly, and implantable sensors for heart failure are replacing or supplementing traditional devices, reducing complications associated with leads.



Segment Analysis Cardiovascular smart implants account for the largest share of the smart implants market, while neurological implants, including closed-loop neuromodulation and brain-computer interfaces, are the fastest-growing segment. Cardiovascular smart implants include connected pacemakers and implantable cardioverter defibrillators, leadless pacemakers such as Abbott's AVEIR and Medtronic's Micra, insertable cardiac monitors that detect arrhythmias, implantable pulmonary artery pressure sensors such as CardioMEMS for heart failure management, and cardiac resynchronisation devices, and they account for the largest share of revenue because of the large number of cardiac device patients and established remote monitoring. Neurological smart implants include closed-loop spinal cord stimulators, adaptive deep brain stimulators, responsive neurostimulators for epilepsy such as NeuroPace's RNS system, vagus nerve stimulators and brain-computer interfaces, and they are growing fastest. Orthopaedic smart implants, including sensor-equipped knee implants and experimental smart spinal and fracture fixation implants, track recovery and implant performance. Metabolic implants, including implantable continuous glucose monitors such as Eversense and research on implantable insulin delivery, serve diabetes patients. Hearing implants, including cochlear implants with connected processors, form another segment. Drug delivery implants and smart stents that monitor blood flow are in development.

Sensing and monitoring implants account for a large share of smart implants, while closed-loop therapeutic implants are the fastest-growing functional category. Monitoring implants collect and transmit physiological data without delivering therapy, including insertable cardiac monitors, pulmonary artery pressure sensors, implantable glucose sensors and sensor-equipped orthopaedic implants, helping clinicians detect problems and guide treatment. Therapeutic implants with connectivity, such as pacemakers, defibrillators and neurostimulators that transmit data and allow remote programming, combine therapy with monitoring. Closed-loop therapeutic implants sense signals and automatically adjust therapy, including adaptive deep brain stimulation that responds to brain signals in Parkinson's disease, closed-loop spinal cord stimulation that responds to spinal cord signals, responsive neurostimulation that detects seizures, and research systems that link glucose sensing with insulin delivery. Brain-computer interfaces record neural activity and translate it into commands for external devices, and some also stimulate the brain. Drug-eluting and smart drug delivery implants release medicines on schedule or in response to signals. Energy harvesting and wireless power technologies enable battery-free implants in some applications.

Wireless connectivity through Bluetooth and dedicated medical radio is the standard communication technology for smart implants, while cloud platforms and AI analytics are central to extracting value from implant data. Wireless communication technologies, including Bluetooth Low Energy, the Medical Implant Communication Service band and inductive near-field links, allow smart implants to transmit data to external readers, bedside monitors and smartphones. Many cardiac devices now connect directly to patients' smartphones rather than dedicated bedside transmitters. Cloud platforms, such as Medtronic CareLink, Abbott Merlin.net, Boston Scientific LATITUDE and Canary Medical's platform, store and analyse data and alert clinicians to important events. AI and machine learning algorithms detect arrhythmias, predict heart failure decompensation, assess recovery after joint replacement and decode neural signals for brain-computer interfaces. Sensors embedded in implants include accelerometers, gyroscopes, pressure sensors, electrochemical sensors, temperature sensors and electrodes that record electrical activity. Batteries, rechargeable systems and wireless power transfer supply energy. Secure software update mechanisms allow manufacturers to fix problems and add features after implantation, subject to regulatory controls. Integration with electronic health records remains a challenge.

Hospitals and specialist cardiology, neurology and orthopaedic centres are the main end users of smart implants, while remote monitoring services and home-based patients form an important part of the ecosystem. Hospitals perform most smart implant procedures, including cardiac device implantation, neurostimulator placement, joint replacements with smart implants and brain-computer interface surgery, often in specialised departments. Cardiology clinics and electrophysiology labs manage large populations of patients with connected cardiac devices, using remote monitoring to schedule follow-up. Neurology and neurosurgery centres implant and program deep brain stimulators, responsive neurostimulators and brain-computer interfaces. Orthopaedic centres and ambulatory surgery centres use smart knee implants and monitor recovery remotely. Diabetes clinics implant and manage implantable glucose sensors. Remote monitoring service providers, including manufacturer services and independent monitoring companies, review implant data on behalf of clinics. Patients at home interact with smart implants through smartphones and home monitors. Research institutions and clinical trial sites conduct studies of brain-computer interfaces and new smart implants. Payers influence adoption through reimbursement for devices and remote monitoring services.

Regional Analysis North America leads the smart implants market because of high adoption of connected cardiac devices, remote monitoring reimbursement and the concentration of brain-computer interface developers, while Europe and Asia-Pacific are significant and growing markets. North America, led by the United States, accounts for the largest share of the smart implants market. The United States has high rates of cardiac device implantation, established reimbursement for remote monitoring of implanted devices, and many of the leading developers, including Medtronic, Abbott, Boston Scientific, Zimmer Biomet, Canary Medical, Neuralink, Synchron, Precision Neuroscience and Paradromics. The FDA approved several landmark smart implants between 2021 and 2025, including Persona IQ, AVEIR DR, Inceptiv, Eversense 365 and adaptive deep brain stimulation, and granted breakthrough designations to several brain-computer interfaces. Canada has growing adoption. Europe is a major market, with high use of cardiac devices, strong research in neurotechnology in Switzerland, Germany, the Netherlands and France, and companies such as Biotronik and Onward Medical, which develops spinal cord stimulation for paralysis. The EU Medical Device Regulation and cybersecurity rules shape market entry. Asia-Pacific is the fastest-growing region, with rising cardiac device use in China, Japan, South Korea and India, and China's government has prioritised brain-computer interface development, with several domestic companies conducting human trials. Australia is home to Cochlear, Saluda Medical and Synchron's early research. Latin America, the Middle East and Africa have smaller markets, with adoption concentrated in private hospitals.

Key Developments April 2025: Precision Neuroscience received 510(k) clearance for its Layer 7 cortical interface for temporary implantation of up to 30 days, a step toward commercial brain-computer interfaces.
2025: Medtronic's BrainSense adaptive deep brain stimulation became the first closed-loop brain stimulation system for Parkinson's disease, adjusting therapy in real time based on brain signals.
September 2024: Senseonics' implantable continuous glucose monitor was approved for use for one year, the longest-lasting continuous glucose monitoring system available.
April 2024: Medtronic's Inceptiv became the first rechargeable closed-loop spinal cord stimulator in the United States, sensing spinal signals and adjusting stimulation automatically.
January 2024: Neuralink implanted its wireless brain-computer interface in a person with paralysis, who used it to control a computer cursor, as part of its first clinical study.
July 2023: Abbott's AVEIR DR became the world's first dual-chamber leadless pacemaker system, with two implants communicating wirelessly to coordinate pacing.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Smart Implants Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Implant Type
• Cardiovascular Smart Implants
• Neurological Smart Implants
• Orthopaedic Smart Implants
• Metabolic Smart Implants
• Hearing Implants

By Function
• Monitoring Implants
• Connected Therapeutic Implants
• Closed-Loop Therapeutic Implants
• Brain-Computer Interfaces

By Technology
• Wireless Connectivity
• Embedded Sensors
• Cloud Platforms and AI Analytics
• Power and Energy Harvesting

By End User
• Hospitals
• Specialist Cardiology, Neurology and Orthopaedic Centres
• Ambulatory Surgery Centres
• Remote Monitoring Services